Published in Oncogene on April 14, 2008
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 3.60
MicroRNAs in NF-kappaB signaling. J Mol Cell Biol (2011) 2.50
miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J (2010) 2.47
MicroRNA and cancer--focus on apoptosis. J Cell Mol Med (2009) 2.44
The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31
Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A (2010) 2.31
MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features. Nucleic Acids Res (2010) 1.94
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol (2010) 1.94
Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells (2009) 1.84
TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene (2010) 1.81
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene (2011) 1.64
MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer (2011) 1.59
Genome-wide survey of microRNA-transcription factor feed-forward regulatory circuits in human. Mol Biosyst (2009) 1.53
ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One (2012) 1.50
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res (2010) 1.48
miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis. Inflamm Bowel Dis (2015) 1.47
Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer (2009) 1.42
Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med (2008) 1.42
Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med (2010) 1.39
Estradiol suppresses NF-kappa B activation through coordinated regulation of let-7a and miR-125b in primary human macrophages. J Immunol (2010) 1.32
Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway. Nucleic Acids Res (2012) 1.24
Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin (2010) 1.23
miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med (2011) 1.21
The role of microRNAs in ovarian cancer. Biomed Res Int (2014) 1.15
Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol (2011) 1.15
MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. Mol Biol Cell (2012) 1.14
Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene (2012) 1.13
TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle (2013) 1.12
MicroRNAs: new regulators of Toll-like receptor signalling pathways. Biomed Res Int (2014) 1.11
Microprocessor of microRNAs: regulation and potential for therapeutic intervention. Mol Cancer (2010) 1.11
Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKKβ, KLF9, and FBLN5. Reprod Sci (2012) 1.11
Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway. Cell Cycle (2011) 1.11
MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKKβ/NF-κB pathway and reduced interleukin-8 expression. Mol Hum Reprod (2011) 1.10
A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells. Gastroenterology (2014) 1.09
The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med (2010) 1.08
NF-κB and cancer: a paradigm of Yin-Yang. Am J Cancer Res (2010) 1.08
The role of microRNAs miR-200b and miR-200c in TLR4 signaling and NF-κB activation. Innate Immun (2012) 1.07
Ovarian cancer stem cells and inflammation. Cancer Biol Ther (2011) 1.06
TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis. Oncotarget (2014) 0.99
Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells. Am J Reprod Immunol (2010) 0.99
MicroRNA dysregulation in the spinal cord following traumatic injury. PLoS One (2012) 0.98
Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Reprod Immunol (2011) 0.98
Role of extracellular and intracellular microRNAs in sepsis. Biochim Biophys Acta (2014) 0.97
The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget (2015) 0.96
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med (2013) 0.95
Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U S A (2014) 0.93
Flexible and versatile as a chameleon-sophisticated functions of microRNA-199a. Int J Mol Sci (2012) 0.93
Minireview: The roles of small RNA pathways in reproductive medicine. Mol Endocrinol (2011) 0.92
MicroRNA dysregulation in spinal cord injury: causes, consequences and therapeutics. Front Cell Neurosci (2014) 0.91
Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes. Front Mol Neurosci (2011) 0.90
Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res (2016) 0.89
Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers. Adv Drug Deliv Rev (2014) 0.88
miR-200c regulates IL8 expression by targeting IKBKB: a potential mediator of inflammation in leiomyoma pathogenesis. PLoS One (2014) 0.88
Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem (2013) 0.88
Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies. Front Immunol (2014) 0.88
IKK inhibition increases bortezomib effectiveness in ovarian cancer. Oncotarget (2015) 0.87
Reduction of the ST6 β-galactosamide α-2,6-sialyltransferase 1 (ST6GAL1)-catalyzed sialylation of nectin-like molecule 2/cell adhesion molecule 1 and enhancement of ErbB2/ErbB3 signaling by microRNA-199a. J Biol Chem (2013) 0.87
miR-199a-5p regulates the expression of metastasis-associated genes in B16F10 melanoma cells. Int J Clin Exp Pathol (2014) 0.86
Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Am J Reprod Immunol (2011) 0.86
Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression. Oncotarget (2016) 0.85
p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene (2014) 0.84
Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol (2014) 0.84
miTALOS v2: Analyzing Tissue Specific microRNA Function. PLoS One (2016) 0.84
Ovulation and extra-ovarian origin of ovarian cancer. Sci Rep (2014) 0.83
Molecular hydrogen regulates the expression of miR-9, miR-21 and miR-199 in LPS-activated retinal microglia cells. Int J Ophthalmol (2013) 0.83
miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. Int J Mol Sci (2015) 0.82
RNAi-based strategies for cyclooxygenase-2 inhibition in cancer. J Biomed Biotechnol (2010) 0.81
Localization and sub-cellular shuttling of HTLV-1 tax with the miRNA machinery. PLoS One (2012) 0.81
Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget (2014) 0.80
MicroRNA roles in the NF- κB signaling pathway during viral infections. Biomed Res Int (2014) 0.80
Recent insights into the role of NF-kappaB in ovarian carcinogenesis. Genome Med (2010) 0.79
Characterization of miRNomes in acute and chronic myeloid leukemia cell lines. Genomics Proteomics Bioinformatics (2014) 0.79
Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer. Biomed Res Int (2014) 0.79
The stretch responsive microRNA miR-148a-3p is a novel repressor of IKBKB, NF-κB signaling, and inflammatory gene expression in human aortic valve cells. FASEB J (2015) 0.78
Regulation of NF-κB signaling by oxidized glycerophospholipid and IL-1β induced miRs-21-3p and -27a-5p in human aortic endothelial cells. J Lipid Res (2014) 0.77
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov (2016) 0.77
Transcriptional regulation of chemokine expression in ovarian cancer. Biomolecules (2015) 0.77
Molecular analysis of pediatric brain tumors identifies microRNAs in pilocytic astrocytomas that target the MAPK and NF-κB pathways. Acta Neuropathol Commun (2015) 0.77
KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med (2009) 0.77
MicroRNAs in acute kidney injury. Hum Genomics (2016) 0.77
Overexpression of miR-199a-5p decreases esophageal cancer cell proliferation through repression of mitogen-activated protein kinase kinase kinase-11 (MAP3K11). Oncotarget (2016) 0.77
Identification of TLR2 and TLR4‑induced microRNAs in human mesenchymal stem cells and their possible roles in regulating TLR signals. Mol Med Rep (2016) 0.76
Identification of the MicroRNA Repertoire in TLR-Ligand Challenged Bubaline PBMCs as a Model of Bacterial and Viral Infection. PLoS One (2016) 0.76
MicroRNAs control transcription factor NF-kB (p65) expression in human ovarian cells. Funct Integr Genomics (2014) 0.76
MicroRNAs in diffuse large B-cell lymphoma. Oncol Lett (2015) 0.76
A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol (Dordr) (2017) 0.75
The Liver MicroRNA Expression Profiles Associated With Chronic Hepatitis C Virus (HCV) Genotype-4 Infection: A Preliminary Study. Hepat Mon (2016) 0.75
Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications. Cell Death Differ (2016) 0.75
MicroRNA-1908-5p contributes to the oncogenic function of the splicing factor SRSF3. Oncotarget (2017) 0.75
Inducible microRNA-214 contributes to the suppression of NF-κB-mediated inflammatory response via targeting myd88 gene in fish. J Biol Chem (2017) 0.75
Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci Rep (2017) 0.75
Inflammation and cancer. Nature (2002) 53.78
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 29.32
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB regulation in the immune system. Nat Rev Immunol (2002) 15.80
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med (2005) 8.49
Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science (1999) 6.20
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13
Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A (2004) 5.89
Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science (2007) 5.54
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Cancer: an inflammatory link. Nature (2004) 3.88
The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE (1999) 3.79
Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer (2005) 3.72
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12
IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol Cell Biol (1999) 2.68
The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett (2004) 2.41
Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res (2001) 1.79
Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol (2007) 1.65
Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene (2003) 1.65
Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res (2002) 1.63
Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol (2004) 1.53
Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res (2001) 1.43
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci U S A (2006) 1.37
Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner. Mol Pharmacol (2006) 1.11
Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig (2004) 1.08
Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells. Cancer Lett (2001) 1.04
Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine (2002) 1.02
Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia (2002) 1.00
Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res (2001) 0.99
Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res (1994) 0.99
5' upstream sequences of MyD88, an IL-6 primary response gene in M1 cells: detection of functional IRF-1 and Stat factors binding sites. Nucleic Acids Res (1995) 0.99
The TNF receptor 1: a split personality complex. Cell (2003) 0.91
Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst (2001) 3.88
Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med (1999) 3.45
The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health (1995) 2.43
CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med (1996) 2.42
Embryonic erythroid differentiation in the human leukemic cell line K562. Proc Natl Acad Sci U S A (1981) 2.42
Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther (2007) 2.38
The role of Fas in autoimmune diabetes. Cell (1997) 2.30
Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain (2000) 2.23
Helicobacter pylori infection and blood groups. Am J Gastroenterol (1996) 2.20
Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev (2001) 2.12
A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A (1990) 2.11
The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol (1989) 2.09
Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Oncogene (2008) 1.93
Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol (1999) 1.91
TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene (2010) 1.81
An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol (1981) 1.80
Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther (2008) 1.74
Postsplenectomy sepsis and mortality in adults. JAMA (1982) 1.70
Three years' experience in video-assisted thoracic surgery (VATS) for spontaneous pneumothorax. J Thorac Cardiovasc Surg (1994) 1.67
Small bowel motility in diabetics. Am J Dig Dis (1969) 1.64
Psychosocial benefits of a cancer support group. Cancer (1986) 1.62
Evidence of gonadal and gonadotropin antibodies in women with a suboptimal ovarian response to exogenous gonadotropin. Obstet Gynecol (1990) 1.62
Advanced squamous cell carcinoma of the cervix with recent normal Papanicolaou tests. Lancet (1980) 1.61
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med (1987) 1.60
Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr (2000) 1.60
A case-control study of cancer of the endometrium. Am J Epidemiol (1982) 1.50
Adenocarcinoma in situ of the cervix: management and outcome. Gynecol Oncol (1999) 1.45
Novel embryonic genes are preferentially expressed by autonomously replicating rat embryonic and neointimal smooth muscle cells. Circ Res (2000) 1.45
Splenic lymphoma with villous lymphocytes in tropical West Africa. Lancet (1992) 1.43
The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J Cell Sci (1996) 1.35
Human globin gene promoter sequences are sufficient for specific expression of a hybrid gene transfected into tissue culture cells. Mol Cell Biol (1987) 1.35
Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J Immunol (1999) 1.34
Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol (1993) 1.33
Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol (2007) 1.30
Toll-like receptors and their role in the trophoblast. Placenta (2005) 1.30
Increased severity and morbidity of acute hepatitis in drug abusers with simultaneously acquired hepatitis B and hepatitis D virus infections. Br Med J (Clin Res Ed) (1985) 1.29
Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett (1999) 1.28
Epidemic hepatitis B with delta-antigenaemia among Dublin drug-abusers. Ir J Med Sci (1982) 1.28
Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol (1992) 1.25
Treatment of ovarian stromal tumors. Am J Obstet Gynecol (1976) 1.22
Distribution of estrogen receptor-beta-like immunoreactivity in rat forebrain. Neuroendocrinology (1997) 1.21
Expression of the co-stimulator molecule B7-1 in pancreatic beta-cells accelerates diabetes in the NOD mouse. Diabetes (1995) 1.21
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20
Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev (1999) 1.19
Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest (2000) 1.18
O- and N-glycosylation of the Leishmania mexicana-secreted acid phosphatase. Characterization of a new class of phosphoserine-linked glycans. J Biol Chem (1994) 1.17
Uncoupling proteins-2 and 3 influence obesity and inflammation in transgenic mice. Int J Obes Relat Metab Disord (2003) 1.15
Comparison of two bowel preparations for colonoscopy: sodium picosulphate with magnesium citrate versus sulphate-free polyethylene glycol lavage solution. Am J Gastroenterol (1998) 1.15
Heme biosynthesis in Friend erythroleukemia cells: control by ferrochelatase. Proc Natl Acad Sci U S A (1979) 1.14
Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene (2012) 1.13
Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol (2000) 1.12
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene (2011) 1.12
Allelic loss in ovarian cancer. Int J Cancer (1993) 1.12
The isolation and characterization of a novel telomerase immortalized first trimester trophoblast cell line, Swan 71. Placenta (2009) 1.11
The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between alpha 4-integrins and vascular cell adhesion molecule-1. J Clin Invest (1994) 1.11
Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer (1987) 1.11
Cloning, sequencing, and expression of the gene encoding methylmalonyl-coenzyme A mutase from Streptomyces cinnamonensis. J Bacteriol (1993) 1.11
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene (2012) 1.10
Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control (2001) 1.10
Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers. Cancer Res (1988) 1.08
Dermatitis as a component of the fetal inflammatory response syndrome is associated with activation of Toll-like receptors in epidermal keratinocytes. Histopathology (2006) 1.08
Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause (1999) 1.07
Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol (2000) 1.07
Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer (2001) 1.07
Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys (1983) 1.06
Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. Circ Res (1994) 1.05
Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int J Radiat Oncol Biol Phys (1989) 1.04
Expression of Toll-like receptors in the human decidua. Histol Histopathol (2007) 1.04
Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer specificity. Gynecol Oncol (1990) 1.03
Pelvic masses in pregnancy: MR imaging. Radiology (1990) 1.02
The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene (2010) 1.02
The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase. Br J Pharmacol (1989) 1.02
Uterine papillary serous carcinoma. Obstet Gynecol (1987) 1.01
Structural organization of the Amy locus in seven strains of Drosophila melanogaster. Nucleic Acids Res (1986) 1.01
Esophageal involvement in pemphigus vulgaris: a clinical, histologic, and immunopathologic study. J Am Acad Dermatol (1991) 1.01
Molecular and cell biologic aspects of erythropoiesis in long-term bone marrow cultures. Blood (1981) 1.01
Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am J Clin Pathol (1990) 1.00
Stage IIIA carcinoma of the uterine cervix. Gynecol Oncol (1986) 1.00
High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. Int J Radiat Oncol Biol Phys (1988) 1.00
Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol (1990) 0.99
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer (2013) 0.99
Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: clinical opinion. Gynecol Oncol (1991) 0.99
Epithelial carcinoma of the ovary: current strategies. Ann Intern Med (1981) 0.98
Obstetric and nonmalignant gynecologic bleeding: treatment with angiographic embolization. Radiology (1987) 0.98
The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat (1999) 0.97
Comparative carcinogenicity of N-isopropyl-alpha-(2-methylhydraziono)-p-toluamide. HCI (procarbazine hydrochloride), its degradation products, other hydrazines, and isonicotinic acid hydrazide. J Natl Cancer Inst (1969) 0.97
Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab (1990) 0.97
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol (1993) 0.97
The role of lymphocyte subsets in accelerated diabetes in nonobese diabetic-rat insulin promoter-B7-1 (NOD-RIP-B7-1) mice. J Exp Med (1998) 0.96
Carcinosarcoma of the ovary. Int J Gynecol Cancer (2007) 0.96